BioRestorative Therapies (NASDAQ:BRTX) Trading 1.3% Higher

BioRestorative Therapies, Inc. (NASDAQ:BRTX) shares were up 1.3% during trading on Friday . The stock traded as high as $1.57 and last traded at $1.53. Approximately 5,443 shares changed hands during trading, a decline of 99% from the average daily volume of 979,865 shares. The stock had previously closed at $1.51.

Analyst Upgrades and Downgrades

Separately, Roth Mkm increased their price target on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th.

BioRestorative Therapies Stock Up 1.3 %

The company’s fifty day moving average is $1.64 and its two-hundred day moving average is $1.50. The stock has a market cap of $10.36 million, a price-to-earnings ratio of -0.66 and a beta of 63.07.

BioRestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.50) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.06. The business had revenue of $0.09 million for the quarter, compared to analyst estimates of $0.03 million. BioRestorative Therapies had a negative net margin of 6,898.28% and a negative return on equity of 107.65%. During the same period last year, the business earned ($0.77) EPS. Sell-side analysts predict that BioRestorative Therapies, Inc. will post -1.83 EPS for the current fiscal year.

Institutional Trading of BioRestorative Therapies

An institutional investor recently bought a new position in BioRestorative Therapies stock. StoneX Group Inc. bought a new stake in BioRestorative Therapies, Inc. (NASDAQ:BRTX) in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 34,850 shares of the company’s stock, valued at approximately $48,000. StoneX Group Inc. owned approximately 0.51% of BioRestorative Therapies at the end of the most recent quarter. 69.38% of the stock is owned by institutional investors and hedge funds.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.